Proactiveinvestors recommends

Additional Information

Market:	ASX
Sector:	Pharma & Biotech
EPIC:	BNO
Latest Price:	0.46 (9.52% )
52-week High:	0.74
52-week Low:	0.37
Market Cap:	158.58M

1 year chart

1 day chart

Bionomics

Bionomics (ASX: BNO) is an Australian based international biotechnology company focused on the discovery and development of innovative small molecule therapeutics forcancer, diseases of the central nervous system (“CNS”) and immune disorders.

The company has generated multiple drug candidates and targets in the therapeutic areas of cancer, anxiety, multiple sclerosis and epilepsy. The company has a strong out-license record in conjunction with its in-house development program which has seen two highly promising drugs enter clinical trials in the past two years.

Bionomics to conduct Phase II clinical trial on its BNC105 anti-cancer drug

Wednesday, December 09, 2009 by Proactive Investors

Australian biotechnology company Bionomics (ASX: BNO) will conduct a Phase II clinical trial of its BNC105 anti-cancer drug on 60 mesothelioma patients at up to twelve centres in Australia.

Dr Deborah Rathjen, managing director of Bionomics said, “This drug has been very promising so far and the company is quickly moving to Phase II trials. We are expecting to report interim results of this trial in patients with mesothelioma in early 2011.”

“This condition has virtually no effective treatments after first line chemotherapy and patients typically have a life expectancy of less than 1 year. The long latency means that we are still to see the peak incidence of mesothelioma over the next decade, she said.”

The Australasian Lung Cancer Trials Group (ALTG) and the NHMRC Clinical Trials Centre (CTC) has been contracted by Bionomics to conduct the clinical trial.

Mesothelioma is a form of cancer that is usually caused by exposure to asbestos. Despite treatment, mainly with chemotherapy and radiation therapy, the disease usually carries a poor prognosis.

The primary objective of the trial is to determine the tumour response rate. Secondary endpoints include progression free survival, quality of life, overall survival and treatment duration.

This follows a successful BNC105 Phase I clinical trial by Bionomics in patients with advanced cancers at the Peter MacCallum Cancer Centre, the Western Hospital, Austin Health and the Royal Melbourne Hospital.

This is the second planned Phase II clinical trial of the anti-cancer properties of BNC105 after the Bionomics announced a US-based Phase II renal cancer trial earlier this year.

BNC105 is a novel anti-cancer agent which is both a vascular disrupting agent (VDA) and an inhibitor of cancer cell proliferation.

Bionomic's strategy is to license BNC105 to a major player to take it eventually to market once the company has Phase II clinical trial data.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.